DK3079719T3 - ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf - Google Patents

ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf Download PDF

Info

Publication number: DK3079719T3
Authority: DK; Denmark
Prior art keywords: siglec; antibodies; methods
Prior art date: 2013-12-09

Application number

DK14869424T

Other languages

English (en)

Inventor

Christopher R Bebbington

Rustom Falahati

Fernandes Carolina Rita Sousa

David John Matthews

Nenad Tomasevic

Jason Williams

John Leung

Original Assignee

Allakos Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-12-09

Filing date

2014-12-09

Publication date

2019-11-18

2014-12-09 Application filed by Allakos Inc filed Critical Allakos Inc

2019-11-18 Application granted granted Critical

2019-11-18 Publication of DK3079719T3 publication Critical patent/DK3079719T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

DK14869424T 2013-12-09 2014-12-09 ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf DK3079719T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361913891P	2013-12-09	2013-12-09
PCT/US2014/069409 WO2015089117A1 (en)	2013-12-09	2014-12-09	Anti-siglec-8 antibodies and methods of use thereof

Publications (1)

Publication Number	Publication Date
DK3079719T3 true DK3079719T3 (da)	2019-11-18

Family

ID=53371783

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK14869424T DK3079719T3 (da)	2013-12-09	2014-12-09	ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf

Country Status (23)

Country	Link
US (4)	US9546215B2 (da)
EP (2)	EP3079719B8 (da)
JP (4)	JP6549143B2 (da)
KR (3)	KR20210125114A (da)
CN (3)	CN114044825A (da)
AU (2)	AU2014363944B2 (da)
BR (1)	BR112016013109B1 (da)
CA (1)	CA2930886C (da)
CY (1)	CY1122329T1 (da)
DK (1)	DK3079719T3 (da)
ES (1)	ES2758508T3 (da)
HR (1)	HRP20192052T1 (da)
HU (1)	HUE047283T2 (da)
IL (3)	IL298470A (da)
LT (1)	LT3079719T (da)
NZ (1)	NZ720769A (da)
PL (1)	PL3079719T3 (da)
PT (1)	PT3079719T (da)
RS (1)	RS59567B1 (da)
SG (2)	SG10201808835QA (da)
SI (1)	SI3079719T1 (da)
WO (1)	WO2015089117A1 (da)
ZA (1)	ZA201603435B (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2939931A1 (en)	2014-02-28	2015-09-03	Christopher Robert Bebbington	Methods and compositions for treating siglec-8 associated diseases
US9616114B1 (en)	2014-09-18	2017-04-11	David Gordon Bermudes	Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10774145B2 (en)	2015-06-17	2020-09-15	Allakos Inc.	Methods and compositions for treating fibrotic diseases
US10604577B2 (en) *	2015-10-22	2020-03-31	Allakos Inc.	Methods and compositions for treating systemic mastocytosis
US11180535B1 (en)	2016-12-07	2021-11-23	David Gordon Bermudes	Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en)	2016-12-07	2021-09-28	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
EP3565597A4 (en) *	2017-01-06	2021-01-13	Allakos Inc.	METHOD AND COMPOSITION FOR TREATMENT OF CHRONIC OBSTRUCTIVE LUNG DISEASE
KR20200015511A (ko) *	2017-05-05	2020-02-12	알라코스 인크.	염증성 위장 장애를 치료하기 위한 방법 및 조성물
CN110831628A (zh)	2017-05-05	2020-02-21	爱乐科斯公司	用于治疗过敏性眼病的方法和组合物
BR112020022236A2 (pt) *	2018-05-04	2021-02-02	Allakos Inc.	métodos e composições para tratamento de urticária crônica
WO2020168271A1 (en) *	2019-02-15	2020-08-20	Allakos Inc.	Methods and compositions for treating mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis
JP2022542472A (ja) *	2019-08-02	2022-10-03	アラコスインコーポレイテッド	抗ｓｉｇｌｅｃ－８抗体および副腎皮質ステロイド薬を投与する方法
JP2022553378A (ja) *	2019-10-24	2022-12-22	アラコスインコーポレイテッド	過敏性腸症候群および機能性ディスペプシアを処置するための方法および組成物
MX2022006026A (es) *	2019-11-19	2022-09-12	Univ Pennsylvania	Anticuerpos monoclonales anti-alfa-sinucleina y metodos que utilizan los mismos.
WO2021247821A1 (en) *	2020-06-03	2021-12-09	The Wistar Institute Of Anatomy And Biology	Monoclonal antibodies against human siglec-9 and use thereof for immunotherapy
WO2022061032A1 (en) *	2020-09-17	2022-03-24	Allakos Inc.	Methods and compositions for treating viral infection
JPWO2022215566A1 (da) *	2021-04-05	2022-10-13
WO2023215907A1 (en) *	2022-05-06	2023-11-09	Seattle Children's Hospital D/B/A Seattle Children's Research Institute	Inhibiting mast cell activation by binding sialic acid-binding immunoglobulin-like lectin-9 (siglec-9)
WO2024043940A1 (en) *	2022-08-25	2024-02-29	Allakos Inc.	Methods and compositions for treating atopic dermatitis

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
USRE30985E (en)	1978-01-01	1982-06-29		Serum-free cell culture media
US4419446A (en)	1980-12-31	1983-12-06	The United States Of America As Represented By The Department Of Health And Human Services	Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4601978A (en)	1982-11-24	1986-07-22	The Regents Of The University Of California	Mammalian metallothionein promoter system
US4560655A (en)	1982-12-16	1985-12-24	Immunex Corporation	Serum-free cell culture medium and process for making same
US4657866A (en)	1982-12-21	1987-04-14	Sudhir Kumar	Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4767704A (en)	1983-10-07	1988-08-30	Columbia University In The City Of New York	Protein-free culture medium
US4965199A (en)	1984-04-20	1990-10-23	Genentech, Inc.	Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
GB8516415D0 (en)	1985-06-28	1985-07-31	Celltech Ltd	Culture of animal cells
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
US4927762A (en)	1986-04-01	1990-05-22	Cell Enterprises, Inc.	Cell culture medium with antioxidant
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en)	1987-03-18	1988-09-22	Medical Research Council	Altered antibodies
US5677425A (en)	1987-09-04	1997-10-14	Celltech Therapeutics Limited	Recombinant antibody
WO1990003430A1 (en)	1988-09-23	1990-04-05	Cetus Corporation	Cell culture medium for enhanced cell growth, culture longevity and product expression
KR0184860B1 (ko)	1988-11-11	1999-04-01	메디칼 리써어치 카운실	단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
US5891693A (en)	1990-01-25	1999-04-06	Alusuisse Holdings A.G.	Recombinant DNA methods vectors and host cells
US5122469A (en)	1990-10-03	1992-06-16	Genentech, Inc.	Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5264365A (en)	1990-11-09	1993-11-23	Board Of Regents, The University Of Texas System	Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5508192A (en)	1990-11-09	1996-04-16	Board Of Regents, The University Of Texas System	Bacterial host strains for producing proteolytically sensitive polypeptides
US5571894A (en)	1991-02-05	1996-11-05	Ciba-Geigy Corporation	Recombinant antibodies specific for a growth factor receptor
EP0940468A1 (en)	1991-06-14	1999-09-08	Genentech, Inc.	Humanized antibody variable domain
EP0604580A1 (en)	1991-09-19	1994-07-06	Genentech, Inc.	EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
EP0605522B1 (en)	1991-09-23	1999-06-23	Medical Research Council	Methods for the production of humanized antibodies
US5587458A (en)	1991-10-07	1996-12-24	Aronex Pharmaceuticals, Inc.	Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions that mediate killing of hiv-infected cells
EP0625200B1 (en)	1992-02-06	2005-05-11	Chiron Corporation	Biosynthetic binding protein for cancer marker
AU4116793A (en)	1992-04-24	1993-11-29	Board Of Regents, The University Of Texas System	Recombinant production of immunoglobulin-like domains in prokaryotic cells
RU2139731C1 (ru)	1992-11-13	1999-10-20	Айдек Фармасьютикалс Корпорейшн (US	Способ лечения, антитела, гибридома
US5885573A (en)	1993-06-01	1999-03-23	Arch Development Corporation	Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
CA2163345A1 (en)	1993-06-16	1994-12-22	Susan Adrienne Morgan	Antibodies
US5639635A (en)	1994-11-03	1997-06-17	Genentech, Inc.	Process for bacterial production of polypeptides
US5840523A (en)	1995-03-01	1998-11-24	Genetech, Inc.	Methods and compositions for secretion of heterologous polypeptides
US5641870A (en)	1995-04-20	1997-06-24	Genentech, Inc.	Low pH hydrophobic interaction chromatography for antibody purification
US6121022A (en)	1995-04-14	2000-09-19	Genentech, Inc.	Altered polypeptides with increased half-life
US5739277A (en)	1995-04-14	1998-04-14	Genentech Inc.	Altered polypeptides with increased half-life
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
GB9603256D0 (en)	1996-02-16	1996-04-17	Wellcome Found	Antibodies
WO1997038123A1 (en)	1996-04-05	1997-10-16	Board Of Regents, The University Of Texas System	Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
US5834597A (en)	1996-05-20	1998-11-10	Protein Design Labs, Inc.	Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6277375B1 (en)	1997-03-03	2001-08-21	Board Of Regents, The University Of Texas System	Immunoglobulin-like domains with increased half-lives
US6083715A (en)	1997-06-09	2000-07-04	Board Of Regents, The University Of Texas System	Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
ES2244066T3 (es)	1997-06-24	2005-12-01	Genentech, Inc.	Procedimiento y composiciones de glicoproteinas galactosiladas.
AU759779B2 (en)	1997-10-31	2003-05-01	Genentech Inc.	Methods and compositions comprising glycoprotein glycoforms
WO1999029888A1 (en)	1997-12-05	1999-06-17	The Scripps Research Institute	Humanization of murine antibody
US6194551B1 (en)	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
ATE375365T1 (de)	1998-04-02	2007-10-15	Genentech Inc	Antikörper varianten und fragmente davon
WO1999054342A1 (en)	1998-04-20	1999-10-28	Pablo Umana	Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
HUP0104865A3 (en)	1999-01-15	2004-07-28	Genentech Inc	Polypeptide variants with altered effector function
JP4368530B2 (ja)	1999-04-09	2009-11-18	協和発酵キリン株式会社	免疫機能分子の活性を調節する方法
CA2388245C (en)	1999-10-19	2012-01-10	Tatsuya Ogawa	The use of serum-free adapted rat cells for producing heterologous polypeptides
WO2001066126A1 (en) *	2000-03-07	2001-09-13	Smithkline Beecham Corporation	Sialoadhesin factor-2 antibodies
US20030092091A1 (en)	2000-03-07	2003-05-15	Abrahamson Julie A.	Sialoadhesin factor-2 antibodies
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en)	2000-10-06	2006-06-20	Kyowa Hakko Kogyo Co., Ltd.	Process for purifying antibody
ES2649037T3 (es)	2000-12-12	2018-01-09	Medimmune, Llc	Moléculas con semividas prolongadas, composiciones y usos de las mismas
CN1555411A (zh)	2001-08-03	2004-12-15	��迨��＼��ɷݹ�˾	抗体-依赖性细胞毒性增大的抗体糖基化变体
US20030157108A1 (en) *	2001-10-25	2003-08-21	Genentech, Inc.	Glycoprotein compositions
US20040093621A1 (en)	2001-12-25	2004-05-13	Kyowa Hakko Kogyo Co., Ltd	Antibody composition which specifically binds to CD20
US7317091B2 (en)	2002-03-01	2008-01-08	Xencor, Inc.	Optimized Fc variants
DE60336548D1 (de)	2002-04-09	2011-05-12	Kyowa Hakko Kirin Co Ltd	Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
AU2003236019A1 (en)	2002-04-09	2003-10-20	Kyowa Hakko Kirin Co., Ltd.	Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism
CA2481920A1 (en)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Antibody composition-containing medicament
US20040110704A1 (en)	2002-04-09	2004-06-10	Kyowa Hakko Kogyo Co., Ltd.	Cells of which genome is modified
AU2003236015A1 (en)	2002-04-09	2003-10-20	Kyowa Hakko Kirin Co., Ltd.	Process for producing antibody composition
WO2003085119A1 (fr)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc$g(g) iiia
US7361740B2 (en)	2002-10-15	2008-04-22	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
PT1572744E (pt)	2002-12-16	2010-09-07	Genentech Inc	Variantes de imunoglobulina e utilizações destas
AU2004279742A1 (en)	2003-10-08	2005-04-21	Kyowa Hakko Kirin Co., Ltd.	Fused protein composition
US20070134759A1 (en)	2003-10-09	2007-06-14	Harue Nishiya	Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
KR101220691B1 (ko)	2003-11-05	2013-01-14	로슈 글리카트 아게	증가된 ｆｃ 수용체 결합 친화성 및 효과기 기능을 가진ｃｄ20 항체
WO2005053742A1 (ja)	2003-12-04	2005-06-16	Kyowa Hakko Kogyo Co., Ltd.	抗体組成物を含有する医薬
EP1761561B1 (en)	2004-01-20	2015-08-26	KaloBios Pharmaceuticals, Inc.	Antibody specificity transfer using minimal essential binding determinants
WO2005116088A2 (en)	2004-05-25	2005-12-08	The Johns Hopkins University	Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
PT3540062T (pt)	2004-11-16	2021-07-06	Humanigen Inc	Permuta de cassete de região variável de imunoglobulina
EP1951740B1 (en)	2005-11-10	2014-07-16	James Paulson	High affinity siglec ligands
WO2007056870A1 (en)	2005-11-21	2007-05-24	The Governors Of The University Of Alberta	Methods and compositions for pharmacologically controlled targeted immunotherapy
US20080226635A1 (en)	2006-12-22	2008-09-18	Hans Koll	Antibodies against insulin-like growth factor I receptor and uses thereof
WO2009135181A2 (en)	2008-05-02	2009-11-05	Seattle Genetics, Inc.	Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
DK2470671T3 (da) *	2009-08-28	2015-02-09	Regeneron Pharma	Antikin- antistoffer, der binder til flere cc-chemokiner
MX2012003404A (es)	2009-09-22	2012-09-12	Volker Sandig	Procedimiento para producir moleculas que contienen estructuras de glicano especializadas.
US8586044B2 (en)	2010-05-28	2013-11-19	Northwestern University	Treatment of chronic pelvic pain syndrome
EP2465873A1 (en)	2010-12-16	2012-06-20	Deutsches Rheuma-Forschungszentrum Berlin	Eosinophils as a therapeutic target
CN109797138A (zh) *	2011-03-06	2019-05-24	默克雪兰诺有限公司	低岩藻糖细胞系及其应用
US9434786B2 (en) *	2012-02-10	2016-09-06	University Of Maryland, Baltimore	Chemoenzymatic glycoengineering of antibodies and Fc fragments thereof
CA2939931A1 (en) *	2014-02-28	2015-09-03	Christopher Robert Bebbington	Methods and compositions for treating siglec-8 associated diseases
US10604577B2 (en) *	2015-10-22	2020-03-31	Allakos Inc.	Methods and compositions for treating systemic mastocytosis
CN110831628A (zh) *	2017-05-05	2020-02-21	爱乐科斯公司	用于治疗过敏性眼病的方法和组合物

2014
- 2014-12-09 BR BR112016013109-6A patent/BR112016013109B1/pt active IP Right Grant
- 2014-12-09 SG SG10201808835QA patent/SG10201808835QA/en unknown
- 2014-12-09 IL IL298470A patent/IL298470A/en unknown
- 2014-12-09 EP EP14869424.3A patent/EP3079719B8/en active Active
- 2014-12-09 US US14/565,370 patent/US9546215B2/en active Active
- 2014-12-09 LT LT14869424T patent/LT3079719T/lt unknown
- 2014-12-09 DK DK14869424T patent/DK3079719T3/da active
- 2014-12-09 PT PT148694243T patent/PT3079719T/pt unknown
- 2014-12-09 SI SI201431406T patent/SI3079719T1/sl unknown
- 2014-12-09 PL PL14869424T patent/PL3079719T3/pl unknown
- 2014-12-09 KR KR1020217032002A patent/KR20210125114A/ko not_active IP Right Cessation
- 2014-12-09 RS RS20191504A patent/RS59567B1/sr unknown
- 2014-12-09 ES ES14869424T patent/ES2758508T3/es active Active
- 2014-12-09 CA CA2930886A patent/CA2930886C/en active Active
- 2014-12-09 CN CN202111165415.0A patent/CN114044825A/zh active Pending
- 2014-12-09 CN CN202111165428.8A patent/CN113861293A/zh active Pending
- 2014-12-09 NZ NZ720769A patent/NZ720769A/en unknown
- 2014-12-09 EP EP19186014.7A patent/EP3611191A1/en active Pending
- 2014-12-09 AU AU2014363944A patent/AU2014363944B2/en active Active
- 2014-12-09 CN CN201480067583.8A patent/CN105916519B/zh active Active
- 2014-12-09 KR KR1020167018130A patent/KR102311761B1/ko active IP Right Grant
- 2014-12-09 SG SG11201604632PA patent/SG11201604632PA/en unknown
- 2014-12-09 WO PCT/US2014/069409 patent/WO2015089117A1/en active Application Filing
- 2014-12-09 KR KR1020237021876A patent/KR20230107382A/ko not_active Application Discontinuation
- 2014-12-09 HU HUE14869424A patent/HUE047283T2/hu unknown
- 2014-12-09 JP JP2016557547A patent/JP6549143B2/ja active Active
2016
- 2016-05-16 IL IL245663A patent/IL245663B/en active IP Right Grant
- 2016-05-19 ZA ZA2016/03435A patent/ZA201603435B/en unknown
- 2016-12-07 US US15/372,268 patent/US20170209556A1/en not_active Abandoned
2019
- 2019-02-15 JP JP2019025337A patent/JP6963577B2/ja active Active
- 2019-05-17 US US16/416,085 patent/US20200054723A1/en not_active Abandoned
- 2019-11-13 HR HRP20192052TT patent/HRP20192052T1/hr unknown
- 2019-11-27 CY CY20191101242T patent/CY1122329T1/el unknown
2020
- 2020-02-25 JP JP2020029472A patent/JP2020078336A/ja not_active Withdrawn
- 2020-06-16 AU AU2020204016A patent/AU2020204016A1/en not_active Abandoned
2021
- 2021-01-13 IL IL280155A patent/IL280155A/en unknown
2022
- 2022-01-26 US US17/585,323 patent/US20220331412A1/en not_active Abandoned
- 2022-04-06 JP JP2022063368A patent/JP2022082715A/ja active Pending

Also Published As

Publication number	Publication date
US20220331412A1 (en)	2022-10-20
CN114044825A (zh)	2022-02-15
KR20230107382A (ko)	2023-07-14
WO2015089117A1 (en)	2015-06-18
SI3079719T1 (sl)	2019-12-31
NZ720769A (en)	2022-10-28
ES2758508T3 (es)	2020-05-05
HUE047283T2 (hu)	2020-04-28
CN105916519A (zh)	2016-08-31
PL3079719T3 (pl)	2020-05-18
BR112016013109A2 (pt)	2017-09-26
AU2014363944A1 (en)	2016-06-09
EP3079719B1 (en)	2019-09-04
AU2020204016A1 (en)	2020-07-02
CY1122329T1 (el)	2021-01-27
EP3079719A1 (en)	2016-10-19
RS59567B1 (sr)	2019-12-31
LT3079719T (lt)	2019-12-10
IL245663A0 (en)	2016-06-30
JP2020078336A (ja)	2020-05-28
SG10201808835QA (en)	2018-11-29
BR112016013109B1 (pt)	2021-05-11
IL245663B (en)	2021-02-28
JP6549143B2 (ja)	2019-07-24
US9546215B2 (en)	2017-01-17
CN113861293A (zh)	2021-12-31
EP3079719A4 (en)	2017-08-02
US20200054723A1 (en)	2020-02-20
US20170209556A1 (en)	2017-07-27
CN105916519B (zh)	2021-10-22
ZA201603435B (en)	2020-08-26
SG11201604632PA (en)	2016-07-28
IL280155A (en)	2021-03-01
HRP20192052T1 (hr)	2020-02-07
JP2017501744A (ja)	2017-01-19
US20150203578A1 (en)	2015-07-23
JP6963577B2 (ja)	2021-11-10
PT3079719T (pt)	2019-12-05
KR20210125114A (ko)	2021-10-15
KR102311761B1 (ko)	2021-10-13
KR20160095113A (ko)	2016-08-10
IL298470A (en)	2023-01-01
AU2014363944B2 (en)	2020-03-26
EP3611191A1 (en)	2020-02-19
CA2930886C (en)	2024-05-21
JP2019076115A (ja)	2019-05-23
JP2022082715A (ja)	2022-06-02
EP3079719B8 (en)	2019-12-04
CA2930886A1 (en)	2015-06-18

Publication	Publication Date	Title
DK3079719T3 (da)	2019-11-18	ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf
DK2970460T3 (da)	2020-06-02	Anti-IL-33-antistoffer og anvendelser deraf
DK3227336T3 (da)	2019-09-16	Anti-CD79b-antistoffer og fremgangsmåder til anvendelse
DK3192812T3 (da)	2020-07-13	Anti-CD3-antistoffer og fremgangsmåder til anvendelse
CL2016001646A1 (es)	2017-06-09	Anticuerpos y fragmentos anti-vista
DK3026062T3 (da)	2020-10-12	Anti-pd-1-antistof og anvendelse deraf
DK3280441T3 (da)	2021-11-15	Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf
DK3258951T3 (da)	2020-04-06	Anti-pvrig antistoffer og fremgangsmåder for anvendelse
DK3089994T3 (da)	2022-07-04	Fabs-in-tandem-immunglobulin og anvendelser deraf
DK3333191T3 (da)	2020-10-26	Anti-C10ORF54-antistoffer og anvendelser deraf
DK3126388T3 (da)	2019-07-29	Anti-EGFRvIII-antistoffer og anvendelser deraf
DK3027209T3 (da)	2020-11-02	Anti-Activin A-antistoffer og anvendelser deraf
DK3043784T3 (da)	2019-07-15	Arylethere og anvendelser deraf
DK3406633T3 (da)	2022-03-28	Multispecifikke antistoffer, multispecifikke aktiverbare antistoffer og fremgangsmåder til anvendelse heraf
DK2956175T3 (da)	2017-11-27	Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
DK2914291T3 (da)	2022-05-16	Anti-komplement-c1s-antistoffer og anvendelser deraf
DK3336106T3 (da)	2020-07-13	Anti-fcrh5-antistoffer
DK3086807T3 (da)	2022-09-19	Antistoffer og fremgangsmåder til anvendelse
DK3003039T3 (da)	2021-05-25	Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser
DK3381917T3 (da)	2021-10-18	Imidazopyridinforbindelser og anvendelser deraf
DK3708583T3 (da)	2022-05-16	Ikke-fucosylerede anti-fgfr2iiib-antistoffer
DK3116911T3 (da)	2019-09-30	Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse
DK3083680T3 (da)	2020-03-16	Humaniserede anti-Tau(pS422)-antistoffer og fremgangsmåder til anvendelse
DK3063144T3 (da)	2021-10-25	Antiparasitære og pesticid-isoxazolinforbindelser
DK2962100T3 (da)	2021-11-01	Tuberkulosebiomarkører og anvendelser deraf